24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
暂无分享,去创建一个
K. Kario | T. Katsuya | Mitsutoshi Kato | H. Urata | N. Tomitani | Hiroshi Kanegae | M. Nishizawa | T. Fujiwara | Kazuaki Uchiyama | Tetsuro Yoshida | J. Osuga | K. Okada | Y. Niijima | T. Asano | Shoji Yamazaki
[1] M. Uder,et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial , 2018, Cardiovascular Diabetology.
[2] Deepak L. Bhatt,et al. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. , 2017, Circulation journal : official journal of the Japanese Circulation Society.
[3] K. Kario,et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring - The NOCTURNE Study. , 2017, Circulation journal : official journal of the Japanese Circulation Society.
[4] Dave L Dixon,et al. Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.
[5] M. Miyata,et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes , 2017, BMC Pharmacology and Toxicology.
[6] H. Woerle,et al. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®. , 2017, Circulation journal : official journal of the Japanese Circulation Society.
[7] C. Cannon,et al. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication , 2016, Hypertension.
[8] Kazuomi Kario,et al. Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event. , 2016, Progress in cardiovascular diseases.
[9] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[10] John M Lachin,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[11] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[12] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.
[13] K. Kario,et al. Differing Effects of Aliskiren/Amlodipine Combination and High‐Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection , 2016, Journal of clinical hypertension.
[14] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[15] K. Kario,et al. Ethnic Differences in the Degree of Morning Blood Pressure Surge and in Its Determinants Between Japanese and European Hypertensive Subjects: Data From the ARTEMIS Study , 2015, Hypertension.
[16] G. Bakris,et al. Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes , 2015, Diabetes Care.
[17] B. Perkins,et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. , 2015, American journal of physiology. Renal physiology.
[18] Satoshi Teramukai,et al. Home Blood Pressure and Cardiovascular Outcomes in Patients During Antihypertensive Therapy: Primary Results of HONEST, a Large-Scale Prospective, Real-World Observational Study , 2014, Hypertension.
[19] I. Tikkanen,et al. Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.
[20] H. Häring,et al. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2014, Diabetes Care.
[21] C. Kovacs,et al. Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial , 2014, Diabetes, obesity & metabolism.
[22] Peilin Shi,et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide , 2013, BMJ Open.
[23] M. Roden,et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.
[24] H. Häring,et al. Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[25] R. Hermida,et al. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. , 2012, American journal of hypertension.
[26] R. Grempler,et al. Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors , 2012, Diabetes, obesity & metabolism.
[27] J. Staessen,et al. Predictive role of the nighttime blood pressure. , 2011, Hypertension.
[28] J. Danesh,et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.
[29] Yasuhiko Tomino,et al. Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] J. Engvall,et al. Masked nocturnal hypertension—a novel marker of risk in type 2 diabetes , 2009, Diabetologia.
[31] V. Bongard,et al. Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. , 2008, Diabetes & metabolism.
[32] H. Parving,et al. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study , 2007, Journal of hypertension.
[33] Yan Li,et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study , 2007, The Lancet.
[34] E. Ingelsson,et al. Diurnal blood pressure pattern and risk of congestive heart failure. , 2006, JAMA.
[35] Daniel Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.
[36] Kazuhiko Ishikawa,et al. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.
[37] Kazuomi Kario,et al. Morning Surge in Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in Elderly Hypertensives: A Prospective Study , 2003, Circulation.